



ONE RIVERFRONT PLAZA  
1037 Raymond Blvd., Suite 600  
Newark, NJ 07102  
T: 973.757.1100  
F: 973.757.1090  
**WALSH.LAW**

Liza M. Walsh  
Direct Dial: (973) 757-1101  
[lwalsh@walsh.law](mailto:lwalsh@walsh.law)

December 21, 2018

**VIA ECF AND FIRST CLASS MAIL**

Hon. Michael A. Shipp, U.S.D.J.  
United States District Court for the District of New Jersey  
Clarkson S. Fisher Building & U.S. Courthouse  
402 East State Street  
Trenton, N.J. 08608

**Re: *Gilead Sciences, Ltd., et al. v. Strides Pharma, Inc., et al.***  
**Civil Action No. 18-11134 (MAS)(DEA)**

Dear Judge Shipp:

This firm, together with Venable LLP, represents Plaintiffs Gilead Sciences, Inc. and Emory University in connection with the above-referenced matter. Enclosed for the Court's consideration is a Stipulation and proposed Order for Dismissal with Prejudice. If the Stipulation and proposed Order meets with Your Honor's approval, we respectfully request that Your Honor sign and have it entered on the docket.

We thank the Court for its consideration of the attached and are available should Your Honor or your staff have any questions or need anything further.

Respectfully submitted,

*s/Liza M. Walsh*

Liza M. Walsh

Enclosure

cc: All Counsel of Record (*via ECF and Email*)

Exhibit A

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

GILEAD SCIENCES, INC. and  
EMORY UNIVERSITY,

Plaintiffs,

v.

STRIDES PHARMA, INC. and STRIDES  
PHARMA GLOBAL PTE LIMITED,

Defendants.

Civil Action No.: 3:18-cv-11134-MAS-  
DEA

**STIPULATION AND [PROPOSED] ORDER FOR DISMISSAL WITH PREJUDICE**

IT IS HEREBY STIPULATED AND AGREED, by Plaintiffs Gilead Sciences, Inc. (“Gilead”) and Emory University (“Emory”) and Defendants Strides Pharma, Inc. and Strides Pharma Global PTE Limited (collectively, “Strides”), through their undersigned counsel and subject to the Court’s approval, as follows:

1. All claims, counterclaims, affirmative defenses, and/or causes of action asserted by the parties against each other in the above-captioned action by and between Gilead, Emory, and Strides are hereby dismissed *with prejudice*;
2. Either party may write to the Court to reopen this matter and restore it to the active docket at any time within sixty (60) days after termination of discussions between the parties to cure any objections raised by the Federal Trade Commission and/or Department of Justice; and
3. Each party shall bear its own costs, expenses, and attorneys’ fees.

Dated: December 21, 2018

GILEAD SCIENCES, INC. and  
EMORY UNIVERSITY

s/Liza M. Walsh

Liza M. Walsh  
Eleonore Ofosu-Antwi  
WALSH PIZZI O'REILLY FALANGA LLP  
One Riverfront Plaza  
1037 Raymond Boulevard, Suite 600  
Newark, NJ 07102  
Tel: 973-757-1100  
Fax: 973-757-1090  
lwalsh@walsh.law

Christopher P. Borello  
Frederick C. Millett  
VENABLE | FITZPATRICK  
Venable LLP, 1290 Avenue of the Americas  
New York, NY 10104  
Tel: (212) 218-2100  
Fax: (212) 218-2200  
cborello@venable.com  
fmillett@venable.com

*Counsel for Plaintiffs Gilead Sciences, Inc.  
and Emory University*

STRIDES PHARMA, INC. and STRIDES  
PHARMA GLOBAL PTE LIMITED

s/Louis H. Weinstein

Andrew J. Miller  
Ajay Kayal  
Louis H. Weinstein  
BUDD LARNER, P.C.  
150 John F. Kennedy Parkway  
Short Hills, NJ 07078  
(973) 379-4800  
lweinstein@buddlarner.com

*Counsel for Defendants Strides Pharma, Inc.  
and Strides Pharma Global PTE Limited*

**IT IS SO ORDERED THIS \_\_\_\_\_ day of \_\_\_\_\_, 2018**

---

Honorable Michael A. Shipp, U.S.D.J.